Mersana falls as FDA puts cancer drug trial on hold

Mersana Therapeutics

13/03/2023 12:57

** Shares of drug developer Mersana Therapeutics Inc
 MRSN.O  fall 10.8% to $4.12 in premarket trading
    ** U.S. FDA has put on hold an early-stage trial testing
company's experimental cancer drug after the death of a
participant - MRSN
    ** The study was testing company's XMT-2056 candidate
    ** As of last close, stock up ~5.5% over the past 12 months

 (Reporting by Mariam Sunny)
 ((Mariam.ESunny@thomsonreuters.com))